December 15th, 2015

Canadian Stocks That Surged Highest Today: $BABY $CRDL $TER

The Market Signal was created as a platform to help investors, if you own (TSX:BABY), (TSX:CRDL) or (TSE:TER) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)

Else Nutrition Launches New Nutrition Product for Toddlers In North America

https://themarketsignal.com/Free-Report/BABY

(Click link above or copy, paste and hit enter in your browser for your report)

Else Nutrition Holdings Inc. (TSX:BABY) was amongst the top gainers in yesterday's trading session gaining 5.73%. The company has launched the first phase of its Marketing campaign behind the launch of its plant-based Complete Toddler Nutrition product in North American. Already Else has engaged around 50 influencers covering various social media channels with a following of over 3.5 million followers for the campaign. The company picked the influencers following their focus on parenting, health, and vegan eating as well as baby food communities.

Also, the company recently launched a novel protein source for toddler nutrition over a year with a proprietary sustainable and clean production process after 120 years.

Cardiol Therapeutics Commences First Phase CardiolRx(TM) Study

https://themarketsignal.com/Free-Report/CRDL

(Click link above or copy, paste and hit enter in your browser for your report)

Cardiol Therapeutics Inc. (TSX:CRDL) was also another stock that gained most in yesterday's trading session jumping 4.91%. The company has commenced its Health Canada-approved first phase CardiolRx(TM) clinical study. CardiolRx offers extra strength formulation for pharmaceutical cannabidiol and has been formulated to offer high standard purity, stability, and consistency in the industry.

The phase 1 clinical study will assess tolerability, safety, and pharmacokinetics of single doses followed with multiple days CardiolRx ascending doses which will be administered orally to 55 healthy volunteers in fed and fasting states. The company will complete the study in Q4 2020 and it believes that it will represent the first approved high concentration cannabidiol formulation study containing less than 5 ppm THC.

Terrascend Reports 169% Growth In Net Sales In Q2 2020

https://themarketsignal.com/Free-Report/TER

(Click link above or copy, paste and hit enter in your browser for your report)

Another stock that gained most in yesterday's session is Terrascend Corp. (TSE:TER) which was up 4.22%. The company had a strong Q2 2020 in which it reported a 36% QoQ and 169% YoY growth in net sales to $47.2 million. Gross Margin increased 56% while adjusted EBITDA was up 131% QoQ to $11.4 million. Cash flow from operations was $10.4 million and for the full year, the company expects net sales of $192 million.

The company has also announced the results of its annual general meeting in which directorship nominees in the management circular of July 14, 2020, were elected as directors. Also, shareholders at the meeting approved the re-appointment if MNP LLP as the auditor of the TerrAsscend.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370852437/2700/2020-09-07T07:50:11

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.